Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia
Potential Pharmacological Effects of Supplemental Quercetin in the Management of Mild to Moderate Hyperuricemia
1 other identifier
interventional
64
1 country
1
Brief Summary
Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2024
CompletedFirst Submitted
Initial submission to the registry
September 8, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedOctober 17, 2024
October 1, 2024
7 months
September 8, 2024
October 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Effect on circulatory uric acid
Change in plasma uric acid level
90 days
Secondary Outcomes (11)
Effect on lipids
90 days
Effect on lipids
90 days
Effect on glycemia
90 days
Effect on glycemia
90 days
Effect on body internal organs muscles
90 days
- +6 more secondary outcomes
Study Arms (3)
Quercetin group
EXPERIMENTALIn this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Quercetin, twice a day for 90 days.
Control group 1
ACTIVE COMPARATORIn this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.
Control group 2
ACTIVE COMPARATORIn this group normouricemic patients (uric acid \< 7 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.
Interventions
Berberine Phytosome® 730 mg \+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract
Eligibility Criteria
You may qualify if:
- Aged between 18 and 75 years.
- Diagnosed with obesity.
- Diagnosed with hypercholesterolemia.
- With or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dL).
- No restrictions on BMI, alcohol consumption, or smoking habits.
You may not qualify if:
- Current use of uric acid-lowering medications (e.g., allopurinol, febuxostat).
- Diagnosed with oncological diseases.
- Diagnosed with neurological diseases.
- Diagnosed with inflammatory bowel diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
S. Orsola-Malpighi Polyclinic Hospital
Bologna, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Clinical Biochemistry and Experimental Medicine
Study Record Dates
First Submitted
September 8, 2024
First Posted
September 19, 2024
Study Start
October 1, 2023
Primary Completion
April 30, 2024
Study Completion
August 31, 2024
Last Updated
October 17, 2024
Record last verified: 2024-10